9 results match your criteria: "Heart Research Institute Ltd[Affiliation]"
Heart
December 2024
The University of Notre Dame Australia School of Medicine, Fremantle, Western Australia, Australia.
Background: Although the prognostic implications of severe mitral regurgitation (MR) are well recognised, they are less clear in moderate MR. We therefore explored the prognostic impact of both moderate and severe MR within the large National Echocardiography Database Australia cohort.
Methods: Echocardiography reports from 608 570 individuals were examined using natural language processing to identify MR severity and leaflet pathology.
Open Heart
December 2024
School of Medicine, The University of Notre Dame, Fremantle, Western Australia, Australia
Open Heart
October 2024
The University of Notre Dame Australia, Fremantle Campus, Fremantle, Perth, Australia.
BMJ Open
January 2024
Heart Research Institute Ltd, Newtown, New South Wales, Australia.
Introduction: Digital health technologies have the potential to provide cost-effective care to remote and underserved populations. To realise this potential, research must involve people not traditionally included. No research focuses on the acceptability and feasibility of older Indigenous people using wearables for early atrial fibrillation (AF) detection.
View Article and Find Full Text PDFOpen Heart
July 2023
School of Medicine, The University of Notre Dame Australia, Fremantle, Western Australia, Australia.
Objective: We developed an artificial intelligence decision support algorithm (AI-DSA) that uses routine echocardiographic measurements to identify severe aortic stenosis (AS) phenotypes associated with high mortality.
Methods: 631 824 individuals with 1.08 million echocardiograms were randomly spilt into two groups.
Open Heart
June 2023
Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Objective: Pulmonary hypertension (PHT) commonly coexists with significant mitral regurgitation (MR), but its prevalence and prognostic importance have not been well characterised. In a large cohort of adults with moderate or greater MR, we aimed to describe the prevalence and severity of PHT and assess its influence on outcomes.
Methods: In this retrospective study, we analysed the National Echocardiography Database of Australia (data from 2000 to 2019).
Heart
August 2023
Department of Cardiology, Royal Prince Albert Hospital, Camperdown, New South Wales, Australia
Objective: Aortic regurgitation (AR) can lead to pulmonary hypertension (PHT). There is a paucity of data on the prognostic importance of PHT in these patients. We therefore aimed to describe the prevalence and prognostic importance of PHT in such patients.
View Article and Find Full Text PDFHeart
August 2023
Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Objective: The significance of pulmonary hypertension (PHT) complicating aortic stenosis (AS) is poorly characterised. In a large cohort of adults with at least moderate AS, we aimed to describe the prevalence and prognostic importance of PHT in such patients.
Methods: In this retrospective study, we analysed the National Echocardiography Database of Australia (data from 2000 to 2019).
DNA Cell Biol
February 1994
Heart Research Institute Ltd, Camperdown, NSW, Australia.
The S100 protein CP-10 (chemotactic protein, 10 kD), a potent chemotactic factor for murine and human polymorphonuclear cells (PMN) and murine monocytes, has been purified in small amounts from supernatants of activated murine spleen cells (Lackmann et al., 1992). To obtain a more abundant source of the protein, CP-10 was expressed in Escherichia coli as a fusion protein with glutathione S-transferase (GST).
View Article and Find Full Text PDF